NovoCure Ltd Cash Flow Statement
NVCR / Health Care|13 years of annual SEC 10-K data (FY2013-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 13 fiscal years. All figures from audited SEC 10-K filings.
NovoCure Ltd used $49M in operating cash flow and negative free cash flow of $76M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$136.2M | -$168.6M | -$207.0M | -$92.5M | -$58.4M | $19.8M | -$7.2M | -$63.6M | -$61.7M | -$131.8M | -$111.6M | -$80.7M | -$77.4M |
| Depreciation & Amortization | $14.7M | $11.2M | $11.0M | $10.6M | $10.3M | $9.2M | $8.5M | $9.0M | $7.7M | $5.7M | $3.2M | $2.0M | $1.2M |
| Operating Cash Flow | -$49.0M | -$26.4M | -$73.3M | $30.8M | $82.8M | $99.1M | $26.6M | -$1.9M | -$33.1M | -$107.6M | -$99.9M | -$74.2M | -$52.7M |
| Capital Expenditures | $26.6M | $42.9M | $27.1M | $21.4M | $24.2M | $15.0M | $10.5M | $6.7M | $7.4M | $5.7M | $4.7M | $849.0K | $2.2M |
| Free Cash Flow | -$75.7M | -$69.2M | -$100.4M | $9.4M | $58.6M | $84.2M | $16.1M | -$8.6M | -$40.5M | -$113.3M | -$104.6M | -$75.1M | -$54.9M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | $5.0K | - | - |
| Dividends Paid | - | - | - | - | - | - | - | - | $0 | $0 | $0 | - | - |
| FCF Margin | -11.6% | -11.4% | -19.7% | 1.8% | 10.9% | 17.0% | 4.6% | -3.5% | -22.9% | -136.7% | -316.0% | - | - |